agenT-797 Updated Nov 11
The next hard catalyst is the U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, with topline data not expected until 2H2027. In the nearer term, watch for any updates on the ARPA-H BoSS program funding allocation and enrollment progress in the ongoing Phase 2 colorectal cancer trial. The company's $7.5M cash position and $1.3M quarterly operating burn suggest a financing event may be needed within 2-3 quarters to fund the ARDS trial through readout.
- agenT-797 generated first-ever pre-commercial product revenue of $0.2M in Q3 2026 from a named-patient access program in Brazil, demonstrating real-world demand and a potential commercial pathway.
- The drug was selected for the ARPA-H BoSS program (Draper-led team, up to $87M in program-wide funding), providing non-dilutive support and government validation of the platform.
- Analyst consensus is strongly bullish: 7 analysts rate the stock a Buy or Strong Buy (mean target $44 vs $10.22 current price, implying ~339% upside), with B. Riley reiterating Buy as recently as October 21, 2026.
- Cash runway is limited: MiNK ended Q3 2026 with only $7.5M in cash, and the $1.3M quarterly operating burn suggests the company may need to raise capital within 2-3 quarters to fund the randomized ARDS trial through its 2H2027 readout, creating dilution risk.
- The randomized Phase 2 ARDS trial (C-1300-02) is early-stage with no placebo-controlled data yet; early positive signals from tiny patient numbers may not replicate in a controlled setting.
- CEO Jennifer Buell sold $73K worth of stock on October 12, 2026, and UBS trimmed its INKT position by ~68% in Q2 2026, signaling insider/institutional caution.